Brabant Pharma

16 Feb 2015

Brabant’s assets include worldwide development and commercialisation rights to Brabafen™, low-dose fenfluramine, for the treatment of Dravet Syndrome, a rare and catastrophic form of intractable epilepsy that begins in infancy.